Pre-treatment 68 Ga-PSMA-11 PET/CT Prognostic Value in Predicting Response to 177Lu-PSMA-I&T Therapy and Patient Survival

被引:2
作者
Eisazadeh, Roya [1 ]
Mirshahvalad, Seyed Ali [1 ,2 ,3 ,4 ]
Schwieghofer-Zwink, Gregor [1 ]
Hehenwarter, Lukas [1 ]
Rendl, Gundula [1 ]
Gampenrieder, Simon [5 ]
Greil, Richard [5 ]
Pirich, Christian [1 ]
Beheshti, Mohsen [1 ]
机构
[1] Paracelsus Med Univ Salzburg, Univ Hosp, Dept Nucl Med, Div Mol Imaging & Theranost, Muellner Hauptstr 48, A-5020 Salzburg, Austria
[2] Univ Med Imaging Toronto UMIT, Univ Hlth Network, Mt Sinai Hosp, Joint Dept Med Imaging, Toronto, ON, Canada
[3] Womens Coll Hosp, Toronto, ON, Canada
[4] Univ Toronto, Toronto, ON, Canada
[5] Paracelsus Med Univ Salzburg, Haematol Med Oncol Haemostaseol & Oncol Ctr, Dept Internal Med 3, Salzburg, Austria
关键词
Prostate cancer; PSMA; Positron emission tomography; Radioligand therapy; Theranostics; Lutetium; RESISTANT PROSTATE-CANCER; RADIOLIGAND THERAPY; ANTIGEN; MULTICENTER; SAFETY;
D O I
10.1007/s11307-024-01900-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose To assess the prognostic value of pre-treatment [Ga-68]Ga-PSMA-11 PET/CT and other baseline clinical characteristics in predicting prostate cancer (PCa) patients response to [Lu-177]Lu-PSMA (PSMA-I&T), as well as patient survival. Procedures In this retrospective study, 81 patients who received [Lu-177]Lu-PSMA-I&T between October 2018 and January 2023 were reviewed. Eligible patients had metastatic castration-resistant PCa, underwent pre-treatment [Ga-68]Ga-PSMA-11 PET/CT, and had serum prostate-specific antigen (PSA) levels available. On PET/CT images, SUVmax, SULmax, SUVpeak, and SULpeak of the most-avid tumoral lesion, as well as SUVmean of the parotid gland (P-SUVmean) and liver (L-SUVmean), were measured. Also, whole-body PSMA tumour volume (PSMA-TV) and total lesion PSMA (TL-PSMA) were calculated. To interpret treatment response after [Lu-177]Lu-PSMA-I&T, a composite of PSA values and [Ga-68]Ga-PSMA-11 PET/CT findings were considered. The outcomes were dichotomised into progressive versus controlled (stable disease or partial response) disease. Then, the association of baseline parameters with patient response was evaluated. Also, survival analyses were performed to assess baseline parameters in predicting overall survival. Results Sixty patients (age:73 +/- 8, PSA:185 +/- 371) were included. Patients received at least one cycle of [Lu-177]Lu-PSMA therapy (median = 4). Overall, half of the patients showed disease progression. In the progressive versus controlled disease evaluation, the highest SULmax, as well as SUVmax and SULmax to both backgrounds (L-SUVmean and P-SUVmean), were significantly correlated with the outcome (p-values < 0.05). In the multivariate analysis, only SULmax to the L-SUVmean remained significant (p-value = 0.038). The best cut-off was 8 (AUC = 0.71). With a median follow-up of 360 days, 11 mortal events were documented. In the multivariate survival analysis, only SULmax to P-SUVmean (cut-off = 2.4; p-value = 0.043) retained significance (hazard ratio = 4.0). Conclusions A greater level of PSMA uptake, specifically higher tumour-to-background uptake in the hottest lesion, may hold substantial prognostic significance, considering both [Lu-177]Lu-PSMA-I&T response and patient survival. These ratios may have the potential to be used for PCa patient selection for radioligand therapy.
引用
收藏
页码:360 / 369
页数:10
相关论文
共 50 条
  • [41] [68Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?
    Kuten, Jonathan
    Sarid, David
    Yossepowitch, Ofer
    Mabjeesh, Nicola J.
    Even-Sapir, Einat
    EJNMMI RESEARCH, 2019, 9 (01)
  • [42] Restaging the Biochemical Recurrence of Prostate Cancer with [68Ga]Ga-PSMA-11 PET/CT: Diagnostic Performance and Impact on Patient Disease Management
    Fourquet, Aloyse
    Lahmi, Lucien
    Rusu, Timofei
    Belkacemi, Yazid
    Crehange, Gilles
    de la Taille, Alexandre
    Fournier, Georges
    Cussenot, Olivier
    Gauthe, Mathieu
    CANCERS, 2021, 13 (07)
  • [43] Assessing the Heterogeneity of Response of [68Ga] Ga-PSMA-11 PET/CT Lesions in Patients With Biochemical Recurrence of Prostate Cancer
    Dell'Oro, Mikaela
    Huff, Daniel T.
    Lokre, Ojaswita
    Kendrick, Jake
    Govindan, Rajkumar Munian
    Ong, Jeremy S. L.
    Ebert, Martin A.
    Perk, Timothy G.
    Francis, Roslyn J.
    CLINICAL GENITOURINARY CANCER, 2024, 22 (05)
  • [44] [68Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?
    Jonathan Kuten
    David Sarid
    Ofer Yossepowitch
    Nicola J. Mabjeesh
    Einat Even-Sapir
    EJNMMI Research, 9
  • [45] Investigation of image-based lesion and kidney dosimetry protocols for 177Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition
    Resch, Sandra
    Fouladgar, Sarah Takayama
    Zacherl, Mathias
    Sheikh, Gabriel T. T.
    Liubchenko, Grigory
    Rumiantcev, Mikhail
    Unterrainer, Lena M. M.
    Wenter, Vera
    Bartenstein, Peter
    Ziegler, Sibylle I. I.
    Ilhan, Harun
    Beyer, Leonie
    Boening, Guido
    Delker, Astrid
    EJNMMI PHYSICS, 2023, 10 (01)
  • [46] 68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
    de Vries, Lisa H.
    Lodewijk, Lutske
    Braat, Arthur J. A. T.
    Krijger, Gerard C.
    Valk, Gerlof D.
    Lam, Marnix G. E. H.
    Rinkes, Inne H. M.
    Vriens, Menno R.
    de Keizer, Bart
    EJNMMI RESEARCH, 2020, 10 (01)
  • [47] 68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
    Lisa H. de Vries
    Lutske Lodewijk
    Arthur J. A. T. Braat
    Gerard C. Krijger
    Gerlof D. Valk
    Marnix G. E. H. Lam
    Inne H. M. Borel Rinkes
    Menno R. Vriens
    Bart de Keizer
    EJNMMI Research, 10
  • [48] Investigation of image-based lesion and kidney dosimetry protocols for 177Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition
    Sandra Resch
    Sarah Takayama Fouladgar
    Mathias Zacherl
    Gabriel T. Sheikh
    Grigory Liubchenko
    Mikhail Rumiantcev
    Lena M. Unterrainer
    Vera Wenter
    Peter Bartenstein
    Sibylle I. Ziegler
    Harun Ilhan
    Leonie Beyer
    Guido Böning
    Astrid Delker
    EJNMMI Physics, 10
  • [49] Combined [68 Ga]Ga-PSMA-11 and low-dose 2-[18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy
    Alberts, Ian
    Schepers, Robin
    Zeimpekis, Konstantinos
    Sari, Hasan
    Rominger, Axel
    Afshar-Oromieh, Ali
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (03) : 951 - 956
  • [50] Combined [68 Ga]Ga-PSMA-11 and low-dose 2-[18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy
    Ian Alberts
    Robin Schepers
    Konstantinos Zeimpekis
    Hasan Sari
    Axel Rominger
    Ali Afshar-Oromieh
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 951 - 956